Home > Insider Trading > Filing (0001487371-21-000027)

Filing Details

Accession Number:: 0001487371-21-000027
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-25 20:37:31
Reporting Period:: 2021-01-21

Accepted Time:: 2021-01-25 20:37:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1487371	Genmark Diagnostics Inc.	GNMK	Surgical & Medical Instruments & Apparatus (3841)	272053069

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1543884	Michael Gleeson	5964 La Place Court Carlsbad CA 92008	Svp, Corp. Accounts	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-21	37,555	$0.00	384,724	No	4	M	Direct
Common Stock	Acquisiton	2021-01-21	27,115	$0.00	411,839	No	4	M	Direct
Common Stock	Acquisiton	2021-01-21	19,166	$0.00	431,005	No	4	M	Direct
Common Stock	Disposition	2021-01-25	33,027	$14.22	397,978	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Market Stock Units	Disposition	2021-01-21	37,555	$0.00	37,555	$0.00
Common Stock	Market Stock Units	Disposition	2021-01-21	27,115	$0.00	27,115	$0.00
Common Stock	Market Stock Units	Disposition	2021-01-21	19,166	$0.00	19,166	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	M	Direct
8,333	No	4	M	Direct
19,167	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	30,069	Indirect	Michael William Gleeson 2012 Irrevocable Trust

Footnotes

The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted market stock units.
Mr. Gleeson is the trustee of the Michael William Gleeson 2012 Irrevocable Trust and has voting and dispositive power with respect to these shares. Mr. Gleeson disclaims beneficial ownership except to the extent of his pecuniary interest therein.
The MSUs vested in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person was eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares on the Issuer's three-year total Shareholder return, as compared to the Nasdaq Composite Index.
The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares on the Issuer's two-year total Shareholder return, as compared to the Nasdaq Composite Index.
Represents the target number of shares which remain subject to the award.
The MSUs vest in three equal installments, on each of December 31, 2020, December 31, 2021, and December 31, 2022; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares on the Issuer's one-year total Shareholder return, as compared to the Nasdaq Composite Index.